Published in Clin Pharmacol Ther on February 02, 2011
Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res (2013) 1.62
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89
Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol (2015) 0.85
An update on the pharmacogenetics of treating hypertension. J Hum Hypertens (2014) 0.84
Advancing management of hypertension through pharmacogenomics. Ann Med (2012) 0.84
G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockers. Circ Cardiovasc Genet (2014) 0.84
In silico screening for agonists and blockers of the β(2) adrenergic receptor: implications of inactive and activated state structures. J Comput Chem (2011) 0.83
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. Glob Cardiol Sci Pract (2014) 0.80
Graph analysis of β2 adrenergic receptor structures: a "social network" of GPCR residues. In Silico Pharmacol (2013) 0.79
A genome-wide association study to identify genomic modulators of rate control therapy in patients with atrial fibrillation. Am J Cardiol (2014) 0.79
Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med (2013) 0.78
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor. PLoS One (2013) 0.78
Biopsychosocial influence on shoulder pain: risk subgroups translated across preclinical and clinical prospective cohorts. Pain (2015) 0.78
Mapping genetic variants associated with beta-adrenergic responses in inbred mice. PLoS One (2012) 0.78
Genetic variation in the β1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. Am Heart J (2013) 0.77
Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. Pharmgenomics Pers Med (2014) 0.77
Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev (2014) 0.76
Genetic variation in the α1A-adrenergic receptor and phenylephrine-mediated venoconstriction. Pharmacogenomics J (2014) 0.76
Adrenergic Receptor Polymorphism and Maximal Exercise Capacity after Orthotopic Heart Transplantation. PLoS One (2016) 0.75
Gene signatures of postoperative atrial fibrillation in atrial tissue after coronary artery bypass grafting surgery in patients receiving β-blockers. J Mol Cell Cardiol (2016) 0.75
Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density. Osteoporos Int (2015) 0.75
Associations between catecholaminergic, GABAergic, and serotonergic genes and self-reported attentional function in oncology patients and their family caregivers. Eur J Oncol Nurs (2014) 0.75
Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke (2017) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry (1994) 4.33
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet (1999) 3.69
Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol (1993) 3.50
GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab (2006) 3.34
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med (2003) 2.83
A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem (1999) 2.78
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A (2006) 2.72
Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature (1999) 2.55
Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A (2001) 2.52
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther (2003) 1.96
Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest (1998) 1.94
G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci U S A (2002) 1.87
Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol (2002) 1.85
G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes. J Biol Chem (2005) 1.82
A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem (2000) 1.65
The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem (2002) 1.63
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics (2005) 1.53
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol (2008) 1.46
Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol (2009) 1.42
Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol (2002) 1.38
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther (2008) 1.37
Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics (2003) 1.32
beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther (2006) 1.31
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail (2009) 1.25
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol (2006) 1.19
Hierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signaling. J Biol Chem (2003) 1.17
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics (2007) 1.15
Pharmacogenetics of beta-blockers. Pharmacotherapy (2007) 1.13
Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol (2001) 1.10
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics (2005) 1.04
Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics (2007) 1.01
alpha 2A/alpha 2C-adrenergic receptor third loop chimera show that agonist interaction with receptor subtype backbone establishes G protein-coupled receptor kinase phosphorylation. J Biol Chem (2000) 1.00
Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther (2005) 1.00
Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes. PLoS One (2010) 0.95
Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study. Circulation (1999) 0.94
HK-2 human renal proximal tubule cells as a model for G protein-coupled receptor kinase type 4-mediated dopamine 1 receptor uncoupling. Hypertension (2010) 0.93
beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens (2008) 0.91
Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol (2008) 0.90
Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics (2010) 0.86
Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survival. BMC Med Genet (2008) 0.84
Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics (2010) 0.83
Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A (2000) 10.27
Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry (1994) 4.33
Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A (1997) 3.89
Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol (1993) 3.50
Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol (1995) 3.27
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med (2000) 3.08
Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A (1998) 3.05
A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem (1993) 2.78
A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem (1999) 2.78
Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation (1998) 2.62
Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet (1995) 2.17
Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest (1995) 2.17
Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest (1998) 1.94
Phosphorylation and desensitization of the human beta 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. J Biol Chem (1995) 1.88
Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci U S A (1999) 1.85
Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation (2001) 1.72
A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem (2000) 1.65
Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J Biol Chem (1992) 1.62
Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
Transgenic overexpression of beta(2)-adrenergic receptors in airway smooth muscle alters myocyte function and ablates bronchial hyperreactivity. J Biol Chem (1999) 1.54
Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. Pharmacogenetics (2000) 1.51
beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med (1998) 1.40
Beta 1- and beta 2-adrenergic receptors display subtype-selective coupling to Gs. Mol Pharmacol (1992) 1.37
Functional receptor coupling to Gi is a mechanism of agonist-promoted desensitization of the beta2-adrenergic receptor. J Recept Signal Transduct Res (2000) 1.35
The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol (1997) 1.25
The alpha 1C-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. Mol Pharmacol (1991) 1.22
Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol (2001) 1.18
The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol (2001) 1.18
Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem (1996) 1.18
Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J Biol Chem (2000) 1.17
Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat (1999) 1.16
Subtype-selective desensitization of alpha 2-adrenergic receptors. Different mechanisms control short and long term agonist-promoted desensitization of alpha 2C10, alpha 2C4, and alpha 2C2. J Biol Chem (1992) 1.15
Long-term agonist exposure induces upregulation of beta 3-adrenergic receptor expression via multiple cAMP response elements. Proc Natl Acad Sci U S A (1992) 1.14
Implications of genetic variability of human beta 2-adrenergic receptor structure. Pulm Pharmacol (1995) 1.13
A proline-rich region of the third intracellular loop imparts phenotypic beta 1-versus beta 2-adrenergic receptor coupling and sequestration. J Biol Chem (1994) 1.10
Human lung cell beta 2-adrenergic receptors desensitize in response to in vivo administered beta-agonist. Am J Physiol (1995) 1.08
Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs. Mol Pharmacol (1994) 1.08
Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J (2006) 1.08
Mechanisms of impaired beta-adrenergic receptor signaling in G(alphaq)-mediated cardiac hypertrophy and ventricular dysfunction. Mol Pharmacol (2000) 1.08
beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J (2000) 1.05
Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res (2000) 1.04
Heterogeneity in beta-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitization of the beta2-adrenergic receptor. J Biol Chem (1997) 1.03
Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of beta-adrenergic receptor dysfunction in the G alpha q overexpressing mouse. FEBS Lett (1999) 1.02
Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling. Biochemistry (1999) 1.02
Pharmacogenetic applications of the Human Genome project. Nat Med (2001) 1.00
The palmitoylated cysteine of the cytoplasmic tail of alpha 2A-adrenergic receptors confers subtype-specific agonist-promoted downregulation. Proc Natl Acad Sci U S A (1994) 1.00
Phosphorylation and functional desensitization of the alpha2A-adrenergic receptor by protein kinase C. Mol Pharmacol (1998) 1.00
alpha 2A/alpha 2C-adrenergic receptor third loop chimera show that agonist interaction with receptor subtype backbone establishes G protein-coupled receptor kinase phosphorylation. J Biol Chem (2000) 1.00
Transgenic overexpression of beta(2)-adrenergic receptors in airway epithelial cells decreases bronchoconstriction. Am J Physiol Lung Cell Mol Physiol (2000) 0.98
Identification of a Gs coupling domain in the amino terminus of the third intracellular loop of the alpha 2A-adrenergic receptor. Evidence for distinct structural determinants that confer Gs versus Gi coupling. J Biol Chem (1995) 0.98
G protein-coupled receptor kinase specificity for phosphorylation and desensitization of alpha2-adrenergic receptor subtypes. J Biol Chem (1996) 0.98
Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation. J Biol Chem (1999) 0.97
Lack of beta 3-adrenergic receptor mRNA expression in adipose and other metabolic tissues in the adult human. Mol Pharmacol (1993) 0.97
Alpha 2A-adrenergic receptor stimulated calcium release is transduced by Gi-associated G(beta gamma)-mediated activation of phospholipase C. Biochemistry (1997) 0.97
Desensitization of myocardial beta-adrenergic receptors during cardiopulmonary bypass. Evidence for early uncoupling and late downregulation. Circulation (1991) 0.96
beta-Adrenergic regulation of cAMP and protein phosphorylation in phospholamban-knockout mouse hearts. Am J Physiol (1997) 0.96
Chimeric mutagenesis of putative G-protein coupling domains of the alpha2A-adrenergic receptor. Localization of two redundant and fully competent gi coupling domains. J Biol Chem (1996) 0.96
Modification of the beta 2-adrenergic receptor to engineer a receptor-effector complex for gene therapy. J Biol Chem (2001) 0.95
An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling. J Biol Chem (2000) 0.95
Four consecutive serines in the third intracellular loop are the sites for beta-adrenergic receptor kinase-mediated phosphorylation and desensitization of the alpha 2A-adrenergic receptor. J Biol Chem (1995) 0.95
Role of beta ARK in long-term agonist-promoted desensitisation of the beta 2-adrenergic receptor. Cell Signal (1998) 0.89
Human alpha 2-adrenergic receptor subtype distribution: widespread and subtype-selective expression of alpha 2C10, alpha 2C4, and alpha 2C2 mRNA in multiple tissues. Mol Pharmacol (1993) 0.89
Two kinases mediate agonist-dependent phosphorylation and desensitization of the beta 2-adrenergic receptor. Symp Soc Exp Biol (1990) 0.89
Targeted transgenic expression of beta(2)-adrenergic receptors to type II cells increases alveolar fluid clearance. Am J Physiol Lung Cell Mol Physiol (2001) 0.88
Effects of thyroid hormone on cardiac beta-adrenergic responsiveness in conscious baboons. Circulation (1997) 0.87
Regulation of responsiveness at D2 dopamine receptors by receptor desensitization and adenylyl cyclase sensitization. Mol Pharmacol (1991) 0.87
Role of the amino terminus of the third intracellular loop in agonist-promoted downregulation of the alpha2A-adrenergic receptor. Biochemistry (1997) 0.87
An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required for agonist-promoted phosphorylation and desensitization. Biochemistry (1995) 0.87
A polymorphism in the thyroid hormone receptor gene is associated with bronchodilator response in asthmatics. Pharmacogenomics J (2012) 0.85
Direct muscarinic cholinergic inhibition of hepatic glucose production in humans. J Clin Invest (1988) 0.85
The pharmacogenetics of asthma: a candidate gene approach. Pharmacogenomics J (2001) 0.84
Genetic variability of the beta2 adrenergic receptor and asthma exacerbations. Thorax (2006) 0.81
Agonist-mediated downregulation of G alpha i via the alpha 2-adrenergic receptor is targeted by receptor-Gi interaction and is independent of receptor signaling and regulation. Biochemistry (1998) 0.81
Identification and functional characterization of alpha(2)-adrenoceptor polymorphisms. Trends Pharmacol Sci (2001) 0.81
Functional alpha 2-adrenergic receptor-Gs coupling undergoes agonist-promoted desensitization in a subtype-selective manner. Biochem Biophys Res Commun (1993) 0.80
Coding block and 5 leader cistron polymorphisms of the beta2-adrenergic receptor. Clin Exp Allergy (1999) 0.78
Subcellular distribution of beta 2-adrenergic receptors delineated with quantitative ultrastructural autoradiography of radioligand binding sites. Circ Res (1992) 0.77
Fusion of beta 2-adrenergic receptor to G alpha s in mammalian cells: identification of a specific signal transduction species not characteristic of constitutive activation or precoupling. Biochemistry (2000) 0.77
Pseudohallucinations: radio reception through shrapnel fragments. Am J Psychiatry (1981) 0.76
Receptor-specific functional properties of beta 2-adrenergic receptor autoantibodies in asthma. Am J Respir Cell Mol Biol (1995) 0.76
Determination of resting energy expenditure utilizing the thermodilution pulmonary artery catheter. Chest (1987) 0.75
Serine 232 of the alpha(2A)-adrenergic receptor is a protein kinase C-sensitive effector coupling switch. Biochemistry (2001) 0.75
Electrical pacing induces adenylyl cyclase in skeletal muscle independent of the beta-adrenergic receptor. Am J Physiol (1992) 0.75
Cerebrospinal fluid xanthochromia with rifampin. Ann Neurol (1982) 0.75
G-protein coupled receptors, nitric oxide, and the IgE receptor in asthma. Am J Respir Crit Care Med (1995) 0.75
Adrenergic receptors are a fallible index of adrenergic denervation hypersensitivity. Scand J Clin Lab Invest (1991) 0.75
Propylhexedrine Intoxication: Clinical Presentation and Pharmacology. South Med J (1982) 0.75
Pharmacogenetics of beta1-adrenergic receptors in heart failure and hypertension. Arch Mal Coeur Vaiss (2006) 0.75